Vitamin D supplementation ameliorates arthritis but does not alleviates renal injury in pristane-induced lupus model

References

• Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2018;32:188–205.
   PubMed Web of Science ®Google Scholar
• Rose T, Dörner T. Drivers of the immunopathogenesis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:321–333.
   PubMed Web of Science ®Google Scholar
• Monticielo OA, Teixeira TDM, Chies JAB, et al. Vitamin D and polymorphisms of VDR gene in patients with systemic lupus erythematosus. Clin Rheumatol. 2012;31:1411–1421.
   PubMedGoogle Scholar
• Cañas CA, Cañas F, Bonilla-Abadía F, et al. Epigenetics changes associated to environmental triggers in autoimmunity. Autoimmunity. 2016;49:1–11.
   PubMed Web of Science ®Google Scholar
• Freitas EC, de Oliveira MS, Monticielo OA. Pristane-induced lupus: considerations on this experimental model. Clin Rheumatol. 2017;36:2403–2414.
   PubMed Web of Science ®Google Scholar
• Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity. 1992;12:143–148.
   PubMed Web of Science ®Google Scholar
• Vaisberg MW, Kaneno R, Franco MF, Mendes NF, et al. Influence of cholecalciferol (Vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. J Clin Lab Anal. 2000;14:91–96.
   PubMed Web of Science ®Google Scholar
• Satoh M, Kumar A, Kanwar YS, Reeves WH, et al. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA. 1995;92:10934–10938.
   PubMed Web of Science ®Google Scholar
• Matheu V, Bäck O, Mondoc E, et al. Dual effects of vitamin D-induced alteration of TH1/TH2 cytokine expression: enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease. J Allergy Clin Immunol. 2003;112:585–592.
   PubMed Web of Science ®Google Scholar
• Oliveira PG, Grespan R, Pinto LG, et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis Rheum. 2011;63:2956–2965.
   PubMedGoogle Scholar
• Zeggar S, Watanabe KS, Teshigawara S, et al. Role of Lgals9 deficiency in attenuating nephritis and arthritis in BALB/c mice in a pristane-induced lupus model. Arthritis Rheumatol. 2018;70:1089–1101.
   PubMed Web of Science ®Google Scholar
• Brenner M, Meng H-C, Yarlett NC, et al. The non-major histocompatibility complex quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation, and joint damage. Arthritis Rheum. 2005;52:322–332.
   PubMedGoogle Scholar
• Potter M, Wax JS. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol. 1981;127:1591–1595.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Parodis I, Levitsky A. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol. 2013;27:341–349.
   PubMed Web of Science ®Google Scholar
• Ali M, Firoz CK, Jabir NR, et al. An insight on the pathogenesis and treatment of systemic lupus erythematosus. Emiddt. 2018;18:110–123.
   Google Scholar
• Guimarães PM, Scavuzzi BM, Stadtlober NP, et al. Cytokines in systemic lupus erythematosus: far beyond Th1/Th2 dualism lupus: cytokine profiles. Immunol Cell Biol. 2017;95:824–831.
   PubMed Web of Science ®Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011–1021.
   PubMed Web of Science ®Google Scholar
• Dankers W, Colin EM, van Hamburg JP, et al. Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential. Front Immunol. 2016;7:697.
   PubMed Web of Science ®Google Scholar
• Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004;13:339–343.
   PubMed Web of Science ®Google Scholar
• Minhas U, Das P, Bhatnagar A. Role of reactive intermediates in the immunopathogenesis of the pristane-induced Balb/c model of lupus. Lupus. 2011;20:1421–1425.
   PubMed Web of Science ®Google Scholar
• Tang B, Matsuda T, Akira S, et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol. 1991;3:273–278.
   PubMed Web of Science ®Google Scholar
• Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2010;37:60–70.
   PubMed Web of Science ®Google Scholar
• Liang B, Gardner DB, Griswold DE, et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119:296–305.
   PubMed Web of Science ®Google Scholar
• Sverrisson K, Axelsson J, Rippe A, et al. Acute reactive oxygen species (ROS)-dependent effects of IL-1β, TNF-α, and IL-6 on the glomerular filtration barrier (GFB) in vivo. Am J Physiol Renal Physiol. 2015;309:F800–F806.
   PubMed Web of Science ®Google Scholar
• Lavi Arab F, Rastin M, Faraji F, et al. Assessment of 1,25-dihydroxyvitamin D3 effects on Treg cells in a mouse model of systemic lupus erythematosus. Immunopharmacol Immunotoxicol. 2015;37:12–18.
   PubMed Web of Science ®Google Scholar
• Herman S, Kny A, Schorn C, et al. Cell death and cytokine production induced by autoimmunogenic hydrocarbon oils. Autoimmunity. 2012;45:602–611.
   PubMed Web of Science ®Google Scholar
• Reeves WH, Lee PY, Weinstein JS, et al. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30:455–464.
   PubMed Web of Science ®Google Scholar
• Jimenez-Boj E, Redlich K, Türk B, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol. 2005;175:2579–2588.
   PubMed Web of Science ®Google Scholar
• Leiss H, Niederreiter B, Bandur T, et al. Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation. Lupus. 2013;22:778–792.
   PubMed Web of Science ®Google Scholar
• Wahono CS, Rusmini H, Soelistyoningsih D, et al. Effects of 1,25(OH)2D3 in immune response regulation of systemic lupus erithematosus (SLE) patient with hypovitamin D. Int J Clin Exp Med. 2014;7:22–31.
   PubMed Web of Science ®Google Scholar
• Huang L, Kong Y, Wang J, et al. Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway. Mol Med Rep. 2015;12:4187–4195.
   PubMed Web of Science ®Google Scholar
• Jiang T, Tian F, Zheng H, et al. Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response. Kidney Int. 2014;85:333–343.
   PubMed Web of Science ®Google Scholar
• Yung S, Cheung KF, Zhang Q, et al. Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis. Clin Dev Immunol. 2013;2013:1.
   Google Scholar
• Dos Santos M, Poletti PT, Favero G, et al. Protective effects of quercetin treatment in a pristane-induced mouse model of lupus nephritis. Autoimmunity. 2018;51:69–80.
   PubMed Web of Science ®Google Scholar
• Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 2001;15:2579–2585.
   PubMed Web of Science ®Google Scholar